Jazz Pharmaceuticals plc

Company Snapshot

Founded: 2003

Entity Type: Public

Employees: 2,800

Region: U.S.

Revenue: $4,069.0 Millions

Revenue Year: 2024

Headquarter: Dublin, Ireland

Key Geographics: U.S., Europe, Other Countries

Corporate Address: Waterloo Exchange Waterloo Road Dublin 4 Ireland Tel. +353-1-634-7800 www.jazzpharma.com

Company Overview

Jazz Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative medicines for serious diseases, particularly those with limited treatment options. Its portfolio includes sleep disorders, epilepsy, and cancer treatments. With a patient-centric and science-driven approach and are actively advancing a robust pipeline of therapeutics in oncology and neuroscience. The organization aims to enhance patients’ and their families’ lives through innovation by developing medicines that significantly aid those with serious illnesses by transforming scientific discoveries into effective treatments.

The company operates in two business segments – Neuroscience and Oncology. There are 2,800 employees as of December 31, 2024, and it have a prominent presence in the U.S., Europe, and around seventy-five countries.

Financial Highlights (FY 2024)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Jazz Pharmaceuticals plc In Reports

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

BCC Research Report: Dive into pharmaceutical drugs market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Nanotechnology in Cancer Treatment: Technologies and Global Markets

BCC Research Report: Dive into Nanotechnology in Cancer Treatments market report includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Psychedelic Drugs: Global Market Outlook

BCC Research Market Report says psychedelic drugs market is projected to grow from $3.7 bln in 2021 to $5.7 bln in 2027, at a compound annual growth rate of 7.5%.

View All Reports

Jazz Pharmaceuticals plc In News

Kennedy Capital Management LLC Buys Shares of 10,367 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat

MarketBeat - Dec 08, 2025

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting - PR Newswire

PR Newswire - Dec 05, 2025

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher - Yahoo Finance

Yahoo Finance - Dec 05, 2025

Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified - simplywall.st

simplywall.st - Nov 18, 2025

Read All News

Company's Business Segments

Oncology and Neuroscience : The company develops and commercializes medicines, particularly for narcolepsy, cancer, pain, and psychiatry, focusing on unmet medical needs.

Applications/End User Industries

Healthcare

Biopharmaceutical

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment